QFT-Plus leads the industry with innovative CD8 technology

Free webinar: What’s the ‘Plus’ in QuantiFERON-TB Gold Plus?

QFT-Plus features innovative CD8 T cell technology that provides clinicians with a more comprehensive picture of a patient’s immune response to TB. Recent publications illustrate the benefits of QFT-Plus technology for at-risk patient populations – including in contact investigation, healthcare worker screening and immunocompromised patients. Join Dr. Masae Kawamura for a discussion of the latest scientific advancements in TB testing and CD8 technology, including a review of recent publications and a discussion of case scenarios applying the insights of QFT-Plus.


Want to learn more about testing with QuantiFERON-TB Gold Plus?

Contact a QFT-Plus expert

CD8 T cells play a critical role in the M. tuberculosis immune response

During M. tuberculosis infection, CD4 T cells play a critical role in immunological control through their secretion of the cytokine IFN-γ (Figure 1). Evidence now also supports a role for CD8 T cells in host defense against M. tuberculosis. CD8 T cells produce IFN-γ and other soluble factors to (1–3):

  • Suppress M. tuberculosis growth
  • Kill infected cells
  • Directly lyse intracellular Mycobacteria

 

Moreover, research indicates that TB-specific CD8 T cells that produce IFN-γ have been:

  • More frequently detected in those with active TB disease vs. latent infection (4, 5)
  • Associated with recent exposure to TB (6)
  • Detectable in active TB subjects with HIV co-infection and young children (7–9)
QFT-Plus IGRA technology.

Figure 1. QFT-Plus IGRA technology. APC, antigen-presenting cell; MHC, major histocompatibility complex.

Potential for additional clinical insights

Research studies indicate the potential for additional clinical information based upon the CD8 T cell response to TB infection. For more information, download our research studies flyer below:

References

1. Turner, J. et al. (1996) Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology 87, 339.
2. Brookes, R.H. et al. (2003) CD8+ T cell-mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human microphages. Eur. J. Immunol. 33, 3293.
3. Stenger, S. et al. (1998) An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282, 121.
4. Day, C.L. et al. (2011) Functional capacity of Mycobacterium tuberculosis specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 187, 2222.
5. Rozot, V. et al. (2013) Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease. Eur. J. Immunol. 43, 1568.
6. Nikolova, M. et al. (2013) Antigen-specific CD4- and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection. Diagn. Microbiol. Infect. Dis. 75, 277.
7. Chicchio, T. et al. (2014) Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. J. Infect. 69, 533.
8. Ongaya, A. et al. (2013) Mycobacterium tuberculosis-specific CD8+ T cell recall in convalescing TB subjects with HIV co-infection. Tuberculosis 93, S60.
9. Lanicioni, C. et al. (2012) CD8+ T cells provide an immunologic signature of tuberculosis in young children. Am. J. Respir. Crit. Care Med. 185, 206.

Product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.

Get in touch with QIAGEN
Follow QIAGEN on: